BioSpace News Archive

Leading players are focusing on introducing novel treatment through research & development to deliver improved results for the patients with acute migraine

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides top line data from BGBC020, a randomised Phase II clinical study evaluating the efficacy and safety of bemcentinib in hospitalised COVID-19 patients.

CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging SARS-CoV-2 variants.

IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.

Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease, announced top-line interim results from a global clinical validation study of its AlzoSure® Predict prognostic biomarker test, which can accurately predict progression to Alzheimer’s disease years before symptoms appear.

Prestige BioPharma Limited and Busan City Government announced that the two organisations have entered into a memorandum of understanding for the establishment of Research and Development centre in Busan, South Korea.

Rising prevalence of viral diseases and increasing preference for branded medicines with higher success rate are driving oral antivirals market

Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary endpoints with results being statistically significant and clinically relevant we commenced the regulatory filing process which ultimately resulted in the timely filing of the submission to the FDA in Q1 as planned.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, provided an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate designed to be both taste-masked and immediate release, in the lead indication, urea cycle disorders.

BioNTech SE, announced that the Supervisory Board has appointed Jens Holstein to the Management Board as Chief Financial Officer.